House Dust Mite Allergy
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Hal AllergyNetherlands - Leiden
2 programs1
1
PURETHAL Mites 50,000 AUeq/mlPhase 31 trial
SUBLIVAC FIX Mite mixturePhase 1/21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Hal AllergyPURETHAL Mites 50,000 AUeq/ml
Hal AllergySUBLIVAC FIX Mite mixture
Clinical Trials (2)
Total enrollment: 633 patients across 2 trials
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)
Start: Sep 2024Est. completion: Aug 2026552 patients
Phase 3Active Not Recruiting
SUBLIVAC FIX Mite Mixture Dose Tolerability Study
Start: May 2015Est. completion: Nov 201581 patients
Phase 1/2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space